Freenome's Colorectal Cancer Test Hits All Study Endpoints, Triggers $70M Milestone
Freenome’s test, however, didn’t meet the thresholds to get a full $100 million milestone payment from Abbott.
Read the full articleYou might also wanna read
LigaChem Bio Secures 14.1 Billion Won Milestone From Ono
LigaChem Biosciences will receive a milestone payment of at least 14.1 billion won from Ono Pharmaceutical after the first patient dosing of
A Biomarker Exploration Study for Predicting Localization of Recurrence and Metastasis in Colorectal Cancer (PROBE Study)
Conditions : Metastatic Colorectal Cancer (CRC) Sponsors : The First Affiliated Hospital with Nanjing Medical University Not yet recruiting
A Study Testing SOT109 for the First Time in Patients, to Assess How Safe SOT109 is, How Well it Works, and How the Body Handles it in Patients With Advanced Colorectal Cancer That Can Not be Removed by Surgery or is Metastatic
Conditions : Colorectal Cancer (Locally Advanced or Metastatic) Interventions : Biological: SOT109 Sponsors : SOTIO Biotech a.s. Not yet rec
NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer
Conditions : Colon Cancer Metastatic Interventions : Drug: Retifanlimab; Drug: Zanzalintinib Sponsors : Northwell Health Not yet recruiting
How a 25-Cent Cancer Pill Became a Hundred-Billion-Dollar Business
The story you just read was made possible by our readers. We hope it inspires you to support ProPublica, so we can continue producing invest
propublica.org·28d ago
Cancer therapy spinout Myricx Bio agrees to US$1.5B acquisition by Novartis
Myricx Bio, a cancer therapy spinout based on research carried out at the Francis Crick Institute and Imperial College London, has reached a
crick.ac.uk·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.